

## Title

### Short title:

Role of gene drives in malaria elimination.

### Long title:

Role of gene drives in malaria elimination strategy: modeling impact and cost-effectiveness in the Democratic Republic of the Congo.

## Authors

N. Metchanun<sup>1\*</sup>, C. Borgemeister<sup>1</sup>, J. von Braun<sup>1</sup>, M. Nikolov<sup>2</sup>, P. Selvaraj<sup>2</sup>, J. Gerardin<sup>2,3</sup>

## Affiliations

<sup>1</sup>Center for Development Research (ZEF), University of Bonn, Genscherallee 3, 53113 Bonn, Germany

<sup>2</sup>Institute for Disease Modeling, 3150 139<sup>th</sup> Ave SE. Bellevue WA 98005, United States

<sup>3</sup>Department of Preventive Medicine, Northwestern University, 710 N Lake Shore Drive, Chicago, IL 60611, United States

\*to whom correspondence should be addressed: [nmetchanun@uni-bonn.de](mailto:nmetchanun@uni-bonn.de)

**One-sentence summary:** We estimate the impact and cost-effectiveness of gene drive mosquitoes, relative to existing interventions, in malaria elimination strategies.

## Abstract

The tremendous burden of malaria has led to renewed efforts on malaria elimination and the development of novel tools for application where existing tools fall short. Gene drive mosquitoes, where transgenes and their associated phenotypes are efficiently propagated to future generations, are under

development to suppress vector populations or render vectors incapable of malaria transmission.

However, the role of gene drives in an integrated elimination strategy is underexplored. Using a spatially explicit agent-based model of malaria transmission in the Democratic Republic of the Congo, we describe the impact of integrating a population suppression driving-Y gene drive into malaria elimination strategies. We find that as long as the driving-Y construct is extremely effective, releases of gene drive mosquitoes can eliminate malaria, and we identify a cost ceiling for gene drive to be cost-effective relative to existing tools. Vector control via gene drive is worth considering as a supplemental intervention when the construct parameters and costs are suitable.

## Introduction

Female *Anopheles* mosquitoes can transmit *Plasmodium* parasites that cause malaria, a life-threatening infectious disease. The most commonly used vector control methods to prevent mosquito bites are sleeping under insecticide-treated mosquito nets (ITNs) and spraying the inside walls of a house with an insecticide, termed indoor residual spraying (IRS) (1). Treatment of symptomatic malaria cases with an artemisinin-based combination therapy (ACT) can effectively manage malaria burden, although access to prompt and quality care remains a barrier. Yet, despite being preventable and treatable, with considerable control successes during the last 20 years (2, 3), malaria still has devastating impacts on health and livelihoods of people around the world. The World Health Organization (WHO) estimates that about 3.7 billion people are at risk of the disease in 97 predominantly tropical countries (3, 4), even though billions of dollars are spent annually on malaria control and elimination. Most malaria cases occur in sub-Saharan Africa (SSA), accounting for 93% of total malaria cases worldwide (3, 5). With 12% of all cases in SSA, the Democratic Republic of Congo (DRC) is the second highest-burden country on the continent (3). Nearly all of the DRC's population lives in high malaria transmission zones (6). Consequently, the disease remains one of the country's most serious public health problems and is the number one cause of death (7, 8).

Despite sustained malaria control strategies, malaria incidence in the DRC has increased in the last few years (3), and more than 40% of children who fell ill because of malaria did not receive adequate care (3, 9). Health system weaknesses and gaps in the coverage of core interventions caused by financial and programmatic limitations are likely responsible for this recent rise in cases (10) and elimination remains elusive. Sustained access to vector control has been a central strategy in the DRC's complex operating environment, where challenges are compounded by domestic political conflicts (8) and insufficient funding for malaria control (11). These challenges emphasize the urgent necessity of developing new strategies for malaria control and elimination for the DRC and beyond (3, 10, 12, 13).

Transgenic mosquitoes carrying gene drives have recently been successfully developed in the laboratory (14). Gene drive is a novel method that includes 'driving' targeted traits from one generation to the next. This process aims to defeat Mendelian inheritance, by which genes have a 50% chance of being inherited by the progeny, and instead gives certain genes a substantially higher or lower probability of inheritance and thereby alters the frequency of such genes in the population. If given a gene that could alter fertility or survival of the target species, this could alter its population size over a few generations (15, 16). In the driving-Y system, the X-shredding process results in male-biased progeny as the Y-chromosome can still be carried through sperm unaffected to be driven to the next generation (17). The system leads to fecundity reduction, the reduction of the potential to produce offspring, that affects the egg batch size and has implications for the success of the driving system (18, 19). Given rising resistance to existing insecticides and antimalarial drugs (20–23), gene drive mosquitoes might hold great potential to accelerate and achieve lasting gains in malaria control (14). The future of gene drives itself also depends on the economic aspect of the technology compared with existing or future alternatives (24). This study assess cost-effectiveness of gene drives together with conventional interventions by estimating Disability-Adjusted Life Years (DALYs), DALYs averted, and cost-effectiveness of vector control methods in the DRC.

Although gene drive has yet to pass the research and development stage and only lead candidates are now in confined cage trials (24), public concern has been voiced over gene-related technologies. Concerns on previously developed genetic controls such as a genetically modified version of *Aedes aegypti* for control of mosquito-transmitted arboviral diseases has led to a debate on whether the technology is suitable for a large-scale implementation (25). At the same time, proof of efficacy presents a challenge and informed decision-making on gene drive releases into the wild will require additional information about potential effectiveness (14, 26).

Disease modeling is a powerful tool that can complement laboratory findings and help develop control strategies involving transgenic mosquitoes. The scientific community, including the WHO and other policy groups, has increasingly recognized the importance of disease modeling in guiding the development of gene drives and genetically modified organisms (14, 27, 28). In this work, we explore for the first time the possible outcomes of applying gene drives as an intervention for malaria control in realistic SSA settings in combination with established control programs - including ITNs and ACT distributions - while also evaluating the economic cost of the resulting programs.

We model areas in eight provinces of the DRC by calibrating the transmission intensity of the selected areas to malaria prevalence estimates from open data sources, accounting for existing intervention coverage, and using local rainfall and temperature to drive seasonality in vector abundance. In each selected province, we determine effective release strategies of gene drive mosquitoes and define parameter regimes of the driving-Y system that result in elimination of malaria. We then simulate various intervention scenarios including both traditional and gene drive approaches to vector control, identify combinations of interventions that lead to malaria elimination, and use modeled predictions of malaria burden to estimate DALYs averted and compare the cost-effectiveness of driving-Y gene drives and existing vector control interventions in the DRC.

## Results

This study uses mathematical modeling to explore the potential role of driving-Y gene drives for malaria control and elimination in the DRC. Models were parameterized to capture malaria transmission in eight provinces that span the range of transmission seasonality and intensity across the DRC. Releasing gene drive mosquitoes lowers parasite prevalence in all modeled locations regardless of transmission intensity but is especially effective in higher-transmission areas (Figure 2, Supplementary 1). Tripling the number of gene drive mosquitoes released from 100 to 300 resulted in slightly lower wildtype vector fraction but similar parasite prevalence reduction. In most locations, a single release of 300 gene drive mosquitoes decreases wildtype vector fraction slightly faster, resulting in faster reduction of parasite prevalence, compared to three releases of 100 mosquitoes with one year between releases.

Successful drives were those with very efficient X-shredding at little to no cost in fertility. Across settings, gene drive was most successful at reducing malaria prevalence when the X-shredding rate was between 0.95 and 1.0 and fecundity reduction ranged from 0 to 0.15 (Figure 3, Supplementary 2). Drives with slightly lower X-shredding rate (0.9 to 0.95) were also effective in settings with lower transmission intensity. For spatial simulations, we selected a release strategy of a single release of 300 gene drive mosquitoes with fecundity reduction between 0 and 0.15 and X-shredding rate between 0.9 and 1.0.

In the lower transmission intensity areas, malaria elimination could be achieved without gene drives when applying at least 80% coverage of both ITNs and ACT. Regardless of transmission intensity, malaria elimination could be achieved by applying gene drives with X-shredding rate of 1.0 in all simulated settings. In the spatial simulation framework, in which each site is modeled as 25 interconnected areas and gene drive mosquitoes are released only in the center of the region, we simulated a range of intervention mixes, using the scenario modeled with current coverage of ITNs and ACT as the baseline comparator. Malaria elimination was achievable without gene drive mosquitoes by combining high coverage of both ITNs and ACT in Haut Katanga (80% coverage of both) while

elimination was not achievable in Kwango, Nord Ubangui, and Kasai Central at these coverage levels, showing the need for new tools and echoing conclusions of the Lancet Commission on Malaria Eradication (29) and WHO's Strategic Advisory Group on Malaria Eradication (30). For all remaining selected areas with moderate to high parasite prevalence (18.6%, 32.6%, and 60.7% in Bas Uele, Equateur, and Kinshasa provinces accordingly) a single release of single species 300 driving-Y mosquitoes with an X-shredding rate of 1.0 and fecundity reduction between 0.05 and 0.15 eliminated malaria within 15 years (Table 2). In the simulations, we assumed all *Plasmodium falciparum* parasite inclusively transmitted by *Anopheles gambiae* as this single species dominates transmission in the DRC, but results are generalizable to other species or to multi-species systems if multiple species-specific drives are released.

Reduction in transmission intensity was more sensitive to changes in X-shredding rate than fecundity reduction in spatial setting when we compared the interventions with and without gene drives to the baseline (Supplementary 3). With gene drive mosquitoes, the models predicted that malaria elimination could be achieved within 7 years, and in many of these scenarios it was achieved 4 years post-release.

DALYs averted estimated from the model's outputs show similar trends as those of WHO (Table S1 in Supplementary 4). Population-level cost-effectiveness estimates for individual and combined interventions as costs per DALY averted in comparison with the baseline scenario indicate that DALYs averted, rather than cost, is the main factor determining cost effectiveness across interventions (Table S2 in Supplementary 4). In scenarios with gene drives that resulted in malaria elimination, the costs per DALYs averted are lower in areas where the transmission intensity is originally higher as there were more DALYs to avert in the high transmission area with comparable costs between scenarios and the costs decrease over time as DALYs continue to be averted after elimination is achieved (Table 3).

The expansion paths of all sites show the order in which interventions would be selected at different levels of resources available based on the incremental cost-effectiveness ratio (ICER). ICER indicates additional costs required to avert each additional DALY by moving from the lower-cost to the higher-cost intervention (31), and is calculated using average yearly costs and yearly effectiveness (Figure 3). Notable differences exist between the first and the following two 5-year intervals. The combination of ITNs and ACT at 95% coverage is the most cost-effective intervention plan. However, it is not clear that 95% coverage of either ACT or ITNs as single interventions or in combination would be achievable under the estimated costs, as even with high expenditures, such levels of coverage have not yet been achieved (29, 32). For the first interval, the high-coverage combinations of ITNs and ACT are more cost-effective (Figure 4 and Table S3 in Supplementary 4). In the following years (second and third intervals; Table S3 in Supplementary 4), the unit cost of gene drive mosquitoes affects the priority of the strategies on the expansion path as gene drives become more cost-effective compared to other interventions (Figure 4).

The cost of gene drives as a single intervention in this study calculated in International Dollar (\$int), a hypothetical unit of currency that has the same purchasing power that the U.S. Dollar (US\$) has in the United States at a given point in time (31), ranged from 0.72 \$int to 7.17 \$int per person per year (Table 1). The calculation is based on costs of gene drives per person in previous studies (51, 77). In case of combinations, the cost of gene drives was added to the cost of other interventions. Using the lower bound price for the cost of gene-edited mosquitoes, gene drive as a single intervention is the most cost-effective intervention overall as gene drive mosquitoes with X-shredding rate of 1.0 could eliminate malaria in all contexts and would be the first choice where resources are limited. The effect, however, could be seen after elimination was achieved from the second 5-year interval onwards. If the malaria elimination cannot be achieved, 95% ACT coverage is the most cost-effective intervention. The result suggests that, if gene drives with 100% effective construct, an X-shredding rate of 1.0 and fecundity reduction of 0.05-0.15 are available, and their cost is comparable to other existing interventions, gene

drives would be the most cost effective single intervention for malaria elimination. It is possible to maintain existing interventions, especially ACT and ITNs, early on, while gene drives are propagating. Once mosquito population collapse, gene drives become more cost-effective over a medium timeframe.

## Discussion

This study uses mathematical modeling to describe the potential role of driving-Y gene drive mosquitoes in malaria control across the transmission spectrum in the DRC, an area where achieving effective control has historically been challenging. Our results suggest that gene drive could be an effective strategy for malaria elimination in the DRC, either as a single intervention or in combination with other interventions. To the best of our knowledge, this is the first study that models the epidemiological impact and cost-effectiveness of gene drive mosquitoes for malaria elimination. Previous studies involving gene drives for malaria control are limited in scope to laboratory experiments (33–36), and to the development and parameterization of mathematical models (37–40). By extending previous modeling work (41) to estimate the cost-effectiveness of gene drive in realistic settings, our work helps fill a gap in evidence about programmatic implementation of gene drives in the context of limited resources. This work also helps gauge the probabilities of success and possible outcomes of gene drives that are strictly laboratory-contained or in transition from the laboratory-based research to future field-based research. In addition to the technical perspective provided in this study, further work is necessary, including on the ethical perspective, i.e., standard research ethics, procedural ethics, and democratizing the technology (42), as a key component to implement this technology in wild mosquito populations (43).

We found that the success of driving-Y gene drives in all areas regardless of vector density highly depends on the ability of gene drives to shred the X chromosome. Though a naturally occurring driving-Y chromosome that transmits >90% of male progeny could be found in *Aedes* and *Culex* mosquitoes (44) and a CRISPR-based X-shredder could generate up to 100% male bias in the laboratory



(45, 46), the adoption of this strategy could be very challenging because it may be difficult to achieve perfect X-shredding rate at every development stage and during implementation while overcoming the challenge of meiotic sex chromosome inactivation (47). Moreover, possible resistant mutants that could convert wildtype genes and spread resistance, especially in *An. gambiae* that cleavage resistant alleles, have already been observed (45).

The success of these gene drives also relies on mosquito population size and enough time for the drives to propagate in the mosquito population. Hence, understanding interactions between existing vector control methods such as ITNs, IRS and sterile insect technique (SIT) that temporarily reduce the mosquito population (48, 49) and gene drives will be important given the methods tamper with mosquito population.

While our models predicted that high coverage with ITNs and high access to treatment with ACTs could eliminate malaria in lower-transmission settings, achieving such high coverages of existing measures is not only extremely difficult but also comes with high implementation and logistical costs (50, 51). It may take much more investment in logistic and systems to achieve 95% coverage of both ITNs and ACT than WHO's estimates applied in the study (Table 1) (32). Even if theoretically achievable, it is highly improbable to sustain necessary coverage levels in the complex operational environment of high disease burden countries like the DRC (52, 53).

Our model results show that tailoring the frequency of releases and the number of gene drive mosquitoes to be released can make malaria elimination achievable within 5 years after a single release of gene drive mosquitoes under certain conditions, including but not limited to no importation of vectors or infections. The importation can sustain transmission and cause resurgences (54). Therefore, future work is necessary to include importation of vectors and infections to address feasibility of release, as well as specify release schedule that is operationally practical and technically necessary for intended deployment areas.

Because of their self-propagating and self-sustaining properties (17), gene drives would likely result in better cost-effectiveness once implemented compared to other genetically engineered mosquitoes previously developed (e.g. SIT). Nonetheless, the payoffs can be observed once malaria elimination is reached - in most cases, after 5-year post-release. This waiting period can be critical given many life losses in the interim in the DRC's context. We based our cost-effectiveness analysis on the unit costs of OX513A (55) and *Wolbachia* infected mosquitoes (56) based on available information considering the limited cost data of genetic control methods. The rationale to apply the cost of gene drives per person protected instead of using the cost per gene drive mosquitoes is to be conservative in approaching the cost estimation given the low number of gene drive mosquitoes released in the models in this study. The range of costs applied in the study partially reflects the reality in the field as the genetic control methods are varied in cost components even though the methods were developed to tackle the same disease under a similar genetic control strategy (57). Future research could explore the cost components of gene drives, especially development and environmental costs that may contribute to changes in its unit cost. The changes in unit cost could affect the cost-effectiveness of the method if the cost is too high. As we demonstrated in the incremental cost-effectiveness ratio analysis, the cost-effectiveness is cost sensitive. The gene drive approach became less cost-effective compared to other strategies once its cost increased.

This study demonstrated a modeling approach applied to *An. gambiae*, the predominant malaria vector in Africa (58). The methodology developed here can be applied to other malaria-transmitting mosquito species, and in settings with multiple major malaria vectors, releasing an equally effective gene drive for each major vector would approximate the impact of targeting *An. gambiae* in this study. The study identified key aspects of both gene drive technology and its implementation that are fundamental for the technology to be a cost-effective component of a malaria control program. Amid uncertainty about vector abundance and its behavior (59) and no importation of infections and wildtype mosquitoes in the models, the study offers an evaluation framework. The framework can be generalized

to look at other gene drive approaches to effectively plan gene drive strategies in malaria control, especially in other high burden countries where parasite transmission intensity varies.

## Materials and Methods

The simulations in this study use Epidemiological MODELing software (EMOD) v2.18 (60), an agent-based, discrete-time, Monte Carlo simulator of malaria transmission with a vector life cycle (61) and within-host parasite and immune dynamics (62, 63). We selected eight representative provinces in the DRC for simulations (Figure 1) in both non-spatial and spatial simulation frameworks. These approaches differ in whether or not vector migration is included. The selection was based on malaria parasite prevalence data from the DRC-Demographic and Health Survey (DRC-DHS) II 2013-14 (64, 65), Malaria Atlas Project (MAP) parasite prevalence estimates (15, 66), and provincial stratification by climate zones, endemicity, and urban/rural (13) to ensure that selected locations spanned the range of transmission intensity across the entire DRC. For each site, simulations were run on a square 25x25 kilometer grid containing 25 nodes, 5 kilometers apart in both the non-spatial framework where no vector migration was present across all nodes and the spatial framework where vector migration was included. The model's outputs of malaria incidence and mortality were then used to assess cost-effectiveness of interventions.

We selected a central node for each simulated province by identifying a survey point from the MAP parasite prevalence survey database (66) such that the 25-node simulation area was entirely within the selected province (67) and used WorldPop population estimates (68) to verify that the central node is populated. Since *An. gambiae* mosquitoes, the only modeled mosquito species, breed primarily in temporary puddles replenished by rainfall and drained through evaporation and infiltration (69), the simulations use climate data to drive the availability of larval habitat, which influences the amount of vectors throughout the year, and thus biting intensity and transmission (61). In both non-spatial and spatial simulation frameworks, seasonality was enforced in the models by setting the seasonality of

larval habitat abundance such that monthly vectorial capacity matched the average monthly vectorial capacity between 2000 to 2015 in two public datasets (v200906 and Sheffield) (70). Daily temperature series was generated for each node as in (71).

We then calibrated the overall larval habitat abundance by scaling the previously fitted seasonality profile such that the model's parasite prevalence was consistent with the mean 2015 annual parasite prevalence of the location from MAP estimates (72). The annual means of estimated parasite rate in children between the ages of two and ten (PfPR<sub>2-10</sub>) from the year 2000 to 2015 were retrieved from MAP rasters (72) for all simulation nodes. For Haut Katanga, the larval habitat multiplier was calibrated so that the average modeled parasite prevalence for years 2013-2015 was close to the MAP estimates for the same period. This adjustment was made due to the site's very low parasite prevalence. We set each node's population to 1,000 individuals and set birth and mortality rates to 36.3 per 1,000 people per year. The simulation was run for 50 years to initialize population immunity.

In the final 10 years of the 50-year initialization period, the following interventions were imposed (13):

ITNs: modeled ITN usage was based on % of children under the age of five (<5) who slept under an ITN the previous night: 6%, 38%, and 56% in 2007, 2010, and 2013, respectively.

Case management of symptomatic cases with Artemisinin-based Combination Therapy (ACTs): 19% of uncomplicated malaria cases in all ages received treatment with artemether-lumefantrine, based on the 2013 DHS survey reporting 19% of febrile children under 5 receiving ACT.

Indoor Residual Spraying (IRS) was not included as less than 1% of the DRC population was protected by IRS between 2007 and 2018 (3, 73).

After the 50-year initialization, simulations were run for the next 15 years in both non-spatial and spatial simulation frameworks. For ITNs used in the model, the initial strength of the blocking effect on indoor mosquito fed on an individual with an ITN was 0.9, and the blocking decayed at an exponential rate with mean 730 days. The initial strength of the killing effect was 0.6, conditionally on a successfully blocked feeding event. The killing effect decayed at an exponential rate with mean 1,460 days. The model assumed an individual who received an ITN had 0.65 probability of using it on any given night, and ITNs were redistributed every 3 years. For ACT, parameters and values used in the model followed (74).

Under the gene drive intervention, females that mate with a male carrying driving-Y will have as offspring wildtype females and males carrying the driving-Y. The fraction of offspring that are driving-Y males is then  $0.5 + 0.5 * (\text{X-shredding rate})$ , and the fraction of offspring that are females is  $0.5 - 0.5 * (\text{X-shredding rate})$ . Only females that mate with a driving-Y male have their fertility reduced and the total egg batch size is reduced by the fecundity reduction for each female that mates with a modified male (41). We varied X-shredding rate from 0.5 to 1.0 and fecundity reduction from 0 to 0.5 for single releases of 300 gene drive mosquitoes. We selected parameter sets of X-shredding rates (0.9, 0.95, 1.0) and fecundity reductions (0.05, 0.1, 0.15) to generate 9 combinations of driving-Y parameters that could eliminate malaria in the non-spatial framework.

In the non-spatial simulation framework, we sampled the number of gene drive mosquitoes released, frequency of release, and driving-Y parameters and evaluated whether malaria was eliminated. The driving-Y gene drive release strategy and parameters were then applied to the spatial simulation framework, where we identified which interventions or combinations of interventions could eliminate malaria in the selected locations. In all simulated scenarios, the interventions, including gene drive mosquitoes, were applied on the first day of year 0 unless indicated otherwise. A scenario was defined as

reaching malaria elimination when all-age parasite prevalence in the model is not detectable, i.e., drops to zero.

In the spatial simulation framework, vectors moved to a randomly-selected adjacent node at a rate of 0.15 per day or on average around 7 days until migration. The rate parameterizes an exponential distribution which is used to draw duration until the vectors migrate. Humans moved between nodes less than 10 km apart with a rate proportional to their distance. ITNs at 50% coverage and ACT at 19% coverage were applied in baseline scenarios, which were used as the main comparator against other scenarios. Each of the individual ITNs and ACT (case management rate with ACT) and the combination of ITNs and ACT was analyzed at three levels of coverage: 50%, 80%, and 95%, following the selected coverage levels in (75). Scenarios that failed to eliminate malaria were re-simulated with the addition of a single release of 300 driving-Y gene drive mosquitoes at the central node on the first day of year 0.

We calculated Disability-Adjusted Life Years (DALY) from model outputs – population by age group, uncomplicated clinical cases, severe cases, and deaths – at year 5, year 10, and year 15 by giving equal weights to years of healthy life lost at young ages and older ages and with 0% discount rate for future lost years of healthy life. The standard life expectancy at the age of death in years, and the DRC's country lifetable (76), and disability weights (77) of moderate (0.051) and severe (0.133) were applied in DALYs calculation. DALYs averted (78, 79) were then calculated by comparing outcomes to those of baseline scenarios.


Costs of all interventions, including gene drive mosquitoes, were calculated standardized to year 2000 without discount rates in order for the results to be comparable to those of previous WHO milestone studies (75, 80). Estimated costs are expressed in international dollars (\$int) (31). Coverage-dependent costs per person per year of applying ITNs, ACT, and the combination of ITNs and ACT were obtained from WHO-CHOICE database (81) and a previous WHO study (80). For scenarios that included gene drive mosquito releases, we assumed the financial cost of gene drives as a single

intervention ranged from 0.72 \$int to 7.17 \$int per person per year (Table 1) based on costs of gene drives per person in previous studies (56, 82) and applied the US government consumer price index (CPI) (83) to adjust for inflation and the cumulative inflation rate to year 2000 values. Costs of gene drive were added to the costs of any underlying intervention(s) also distributed (Table 1). Cost-effectiveness was calculated for each 5-year interval beginning in 2015 by dividing average yearly costs in \$int by average yearly effectiveness in DALYs averted (31). More cost-effective interventions were identified by drawing a graph of an expansion path through ICER, which uses monetary value to compare the interventions (31), and selecting interventions with more favorable cost-effectiveness.

## Figures and Tables

**Figure 1** Locations of central nodes of the 25x25km simulation areas.

The table describes the main determinants and rural/urban classification of the areas, and Malaria Atlas Project (MAP) estimated the 2015 parasite prevalence of the central nodes that were used in calibration in this study.



Province	Main determinant	MAP 2015 Parasite prevalence at center (%)	Area (urban or rural)
Nord Kivu	Mountain facies, hypoendemic zone	8.7	Rural
Haut Katanga	Equatorial and tropical facies, meso endemic zone	18.5	Rural
Kwango		32.0	Rural
Equateur		32.6	Rural
Kasai Central	Tropical facies, hyper endemic	37.5	Rural
Nord Ubangui		19.8	Rural
Bas Uele		18.6	Urban




Kinshasa	Urban context, with variations from the city center to the periphery	60.7	Urban
----------	--	------	-------

**Table 1** Estimates of costs of interventions per year per one million population applied in the study.


		Interventions	Coverage (%)	Cost per year (\$int, millions) per one million population [i.e. cost per capita] using 2000 base year	
Scenarios without gene drives		Insecticide-treated bed nets (ITNs)	50	0.47	
		Insecticide-treated bed nets (ITNs)	80	0.63	
		Insecticide-treated bed nets (ITNs)	95	0.71	
		Case management with artemisinin-based combination therapy (ACT)	50	0.19	
		Case management with artemisinin-based combination therapy (ACT)	80	0.20	
		Case management with artemisinin-based combination therapy (ACT)	95	0.21	
		Combination (ITNs & ACT)	50	0.68	
		Combination (ITNs & ACT)	80	0.82	
		Combination (ITNs & ACT)	95	0.74	
				<b>Lower bound</b>	<b>Upper bound</b>
Scenarios with gene drives		300 gene drive mosquitoes with X-shredding rates = 1.0 alone	NA	0.72	7.17
		ITNs plus gene drives with X-shredding rates = 0.95 and 1.0	80	1.35	7.80
		ITNs plus gene drives with X-shredding rates = 0.95 and 1.0	95	1.43	7.88

	ACT plus gene drives with X-shredding rates = 0.95 and 1.0	95	0.93	7.38
	ITNs+ACT plus gene drives with X-shredding rates = 0.95 and 1.0	50	1.40	7.85
	ITNs+ACT plus gene drives with X-shredding rates = 0.95 and 1.0	80	1.54	7.99
	ITNs+ACT plus gene drives with X-shredding rates = 0.9, 0.95 and 1.0	95	1.46	7.91

**Figure 2** Characteristic non-spatial model output time series from testing a single release of 100, 200, and 300 driving-Y gene drive mosquitoes at year 0 and multiple releases of 100 gene drives at year 0, year 1, and year 2. Results from Equateur site presented here, see Supplementary 1, Non-spatial simulation framework: number and frequency of driving-Y gene drive mosquitoes released, for remaining sites.



**Figure 3** Simulation outputs, observed at the end of 15-year simulation timeframe, post-release of 300 gene drive mosquitoes at year 0 in non-spatial framework of eight study locations by driving-Y parameter values, see Supplementary 2, Non-spatial simulation framework: driving-Y parameters of gene drive mosquitoes released, for post-releases of 100 and 200 gene drive mosquitoes.



**Table 2** EMOD simulation outcomes when adding 300 gene drive mosquitoes to scenarios that previously failed to achieve malaria elimination within the 15-year timeframe

Table 2 shows the minimum intervention or combination that could achieve malaria elimination in each target location within 15 years after adding driving-Y mosquitoes into the scenarios. In the scenarios that gene drives were applied, the simulations were carried out to see if the gene drives with highly varied X-shredding rates could eliminate malaria in study locations. The X-shredding rate in the table is the lowest X-shredding rate that could result in malaria elimination.

Province	The <u>minimal intervention(s)</u> that could achieve malaria elimination								
	Elimination is possible with interventions at pre-existing levels.								
Intervention	ITNs			ACT			ITNs+ACT		
Coverage	50%	80%	95%	50%	80%	95%	50%	80%	95%
Kwango	1.0	1.0	0.95	1.0	1.0	1.0	1.0	0.95	NA
Equateur	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.95	0.9
Haut Katanga	1.0	0.95	0.95	1.0	1.0	0.95	0.95	NA	NA
Nord Ubangui	1.0	1.0	0.95	1.0	1.0	1.0	1.0	0.95	NA
Kasai Central	1.0	1.0	0.95	1.0	1.0	1.0	1.0	0.95	NA
Bas Uele	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.95	0.9
Kinshasa	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.95	0.9

Notes for Table 2:

Orange color: malaria elimination without gene drives	ITNs: insecticide-treated nets
Blue color: malaria elimination with gene drives	
1.0: gene drives with X-shredding rate = 1.0	

0.95: gene drives with X-shredding rates = 0.95 and 1.0  0.9: gene drives with X-shredding rates = 0.9, 0.95 and 1.0	ACT: case management with artemisinin-based combination treatment (Artemether + Lumefantrine)
NA: not applicable, gene drives were not applied in the scenarios because the scenarios could achieve malaria elimination with the indicated intervention or combination without gene drives.	

**Table 3** Average yearly cost per one million population and mean parasite prevalence reduction from baseline of interventions and combinations applied in the study.

	Intervention	Cover-age	WHO's	Estimates from model's outputs								Transmissi on intensity
			Average yearly costs per one million population (\$int, million)	Mean parasite prevalence reduction from baseline over 15 years (%)	The first interval: year 1-5		The second interval: year 6-10		The last interval: year 11-15			
					Yearly cost (\$int, million) per million population	Mean parasite prevalence reduction from baseline (%)	Yearly cost (\$int, million) per million population	Mean parasite prevalence reduction from baseline (%)	Yearly cost (\$int, million) per million population	Mean parasite prevalence reductio n from baseline (%)		
Scenarios without gene drives	ITNs	50%	0.47	0.48	-0.03	0.47	-0.05	0.48	-0.03	0.5	-0.03	Low
				0.47	-0.03	0.47	-0.03	0.46	-0.02	0.47	-0.02	Medium
				0.48	-0.02	0.48	-0.03	0.48	-0.02	0.48	-0.02	High
	80%	0.63	0.63	0.08	0.63	0.13	0.62	0.06	0.63	0.05	Low	

			0.63	0.06	0.63	0.10	0.64	0.06	0.63	0.03	Medium		
			0.57	0.05	0.63	0.08	0.45	0.05	0.63	0.02	High		
			95%	0.71	0.71	0.23	0.71	0.23	0.71	0.23	0.71	0.23	Low
					0.70	0.11	0.71	0.15	0.69	0.10	0.7	0.07	Medium
					0.69	0.10	0.71	0.15	0.66	0.09	0.71	0.05	High
			ACT	50%	0.19	0.19	-0.08	0.19	-0.14	0.19	-0.06	0.19	-0.04
	0.19	-0.04				0.19	-0.06	0.19	-0.04	0.19	-0.01	Medium	
	0.19	-0.02				0.19	-0.04	0.19	-0.03	0.19	0.00	High	
	80%	0.2		0.21	0.01	0.22	-0.02	0.21	0.03	0.21	0.04	Low	
				0.20	0.02	0.2	0.01	0.2	0.02	0.2	0.04	Medium	
				0.20	0.03	0.2	0.03	0.2	0.03	0.2	0.05	High	
	95%	0.21		0.21	0.11	0.21	0.08	0.21	0.13	0.21	0.12	Low	
				0.21	0.10	0.21	0.12	0.21	0.09	0.21	0.10	Medium	
				0.21	0.09	0.21	0.09	0.21	0.09	0.21	0.09	High	
	ITNs & ACT	50%	0.68	0.69	0.07	0.68	0.10	0.7	0.07	0.69	0.06	Low	
0.68				0.06	0.68	0.08	0.68	0.05	0.67	0.04	Medium		

				0.68	0.05	0.68	0.06	0.68	0.05	0.68	0.04	High				
		80%	0.82	0.82	0.36	0.82	0.26	0.82	0.40	0.82	0.42	Low				
				0.82	0.28	0.82	0.36	0.82	0.25	0.81	0.23	Medium				
				0.82	0.23	0.82	0.27	0.82	0.22	0.81	0.18	High				
		95%	0.74	0.74	0.36	0.74	0.27	0.74	0.40	0.74	0.42	Low				
				0.74	0.48	0.74	0.43	0.74	0.49	0.74	0.51	Medium				
				0.74	0.42	0.74	0.43	0.74	0.41	0.74	0.40	High				
<b>Cost calculation range</b>				<b>Lower bound</b>	<b>Upper bound</b>		<b>Lower bound</b>	<b>Upper bound</b>		<b>Lower bound</b>	<b>Upper bound</b>					
Scenarios with gene drives	300 gene drive mosquitoes with X-shredding rates = 1.0 alone	NA	NA	0.72	7.17	0.23	0.72	7.15	-0.13	0.72	7.18	0.40	0.72	7.18	0.42	Low
				0.80	7.94	0.36	0.95	9.47	0.08	0.72	7.17	0.48	0.72	7.17	0.51	Medium
				0.72	7.17	0.36	0.72	7.16	0.04	0.72	7.17	0.51	0.72	7.17	0.53	High
	ITNs plus gene drives	80	NA	1.35	7.81	0.28	1.35	7.83	0.04	1.35	7.81	0.39	1.35	7.8	0.41	Low
				NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA



with X-shredding rates = 0.95 and 1.0			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High	
ITNs plus gene drives with X-shredding rates = 0.95 and 1.0	95	NA	1.43	7.89	0.33	1.43	7.89	0.16	1.43	7.89	0.40	1.43	7.88	0.42	Low	
			1.43	7.88	0.42	1.43	7.88	0.26	1.43	7.88	0.48	1.43	7.88	0.51	Medium	
			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High
ACT plus gene drives with X-shredding rates = 0.95 and 1.0	95	NA	0.93	7.39	0.32	0.93	7.39	0.14	0.93	7.39	0.40	0.93	7.39	0.42	Low	
			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium
			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High
ITNs & ACT plus gene drives with X-shredding	50	NA	1.40	7.86	0.32	1.4	7.86	0.16	1.4	7.86	0.40	1.4	7.85	0.42	Low	
			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium
			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High

rates = 0.95 and 1.0															
ITNs & ACT plus gene drives with X-shredding rates = 0.95 and 1.0	80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Low
			1.54	7.99	0.46	1.54	7.99	0.38	1.54	7.99	0.49	1.54	7.99	0.51	Medium
			1.54	7.99	0.47	1.54	7.99	0.36	1.54	7.99	0.51	1.54	7.98	0.53	High
ITNs & ACT plus gene drives with X-shredding rates = 0.9, 0.95 and 1.0	95	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Low
			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Medium
			1.46	7.91	0.49	1.46	7.9	0.44	1.46	7.91	0.51	1.46	7.93	0.53	High

Note for Table 3: 1) It is possible that the DALY averted results turned out to be negative figures in some scenarios since the combination of ITNs at 50% coverage and ACT at 19% coverage was applied in the baseline scenarios (comparator). For example, a 50%ITNs scenario means only ITNs were applied as a single intervention in the scenario; thus, it is understandable that the lower efficacy of 50%ITNs alone could be observed once compared to the comparator, which the combination of 50%ITNs and 19% ACT was applied.

2) Scenarios that could achieve malaria elimination are in green. NA = Not Applicable, highlighted in grey.


3) Transmission intensity in study areas:

Low: Haut Katanga

Medium: Kwango, Kasai Central, Nord Ubangui

High: Bas Uele, Kinshasa, Equateur

**Figure 4** Cost-effectiveness plane showing 16 analyzed interventions (10 individual and combination interventions at three assumed coverage levels) and expansion path for year 1-5, year 6-10, and year 11-15



## References and Notes

1. WHO, *Guidelines for malaria vector control* (2019); <https://www.who.int/malaria/publications/atoz/9789241550499/en/>.
2. WHO, “Eliminating Malaria” (2016), (available at <http://www.who.int>).
3. WHO, “World Malaria Report” (2019), (available at <https://www.who.int/publications-detail/world-malaria-report-2019>).
4. UNICEF, Malaria in Africa. *Monitoring the situation of children and women* (2019), (available at <https://data.unicef.org/topic/child-health/malaria/>).
5. WHO, Malaria. *Fact sheets* (2020), (available at <https://www.who.int/news-room/fact-sheets/detail/malaria>).
6. Vector Link, Democratic Republic of the Congo (2019), (available at <https://pmivectorlink.org/where-we-work/drc/>).
7. IHME, Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Global Health Metrics*. **392**, 1736–1788 (2018).
8. N. R. Ngatu, S. Kanbara, A. Renzaho, R. Wumba, E. P. Mbelambela, S. M. J. Muchanga, B. A. Muzembo, N. Leon-Kabamba, C. Nattadech, T. Suzuki, N. Oscar-Luboya, K. Wada, M. Ikeda, S. Nojima, T. Sugishita, S. Ikeda, Environmental and sociodemographic factors associated with household malaria burden in the Congo. *Malaria Journal*. **18**, 53 (2019).
9. Unitaid, “Disease Narrative for Malaria” (2019), (available at <https://unitaid.org/assets/Malaria-Disease-narrative.pdf>).
10. Malaria Policy Advisory Committee Meeting, “Universal access to core malaria interventions in high-burden countries” (2018), (available at <http://www.who.int/malaria/mpac/mpac-april2018-universal-access-core-interventions-session8.pdf>).
11. M. G. Head, S. Goss, Y. Gelister, V. Alegana, R. J. Brown, S. C. Clarke, J. R. A. Fitchett, R. Atun, J. A. G. Scott, M. L. Newell, S. S. Padmadas, A. J. Tatem, Global funding trends for malaria research in sub-Saharan Africa: a systematic analysis. *The Lancet Global Health*. **5**, e772–e781 (2017).

12. Roll Back Malaria Partnership, RBM Partnership Strategic Plan 2017 – 2020 (2017).
13. President’s Malaria Initiative, FY 2019 Democratic Republic of Congo Abbreviated Malaria Operational Plan (2019) (available at <https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy19/fy-2019-democratic-republic-of-the-congo-abbreviated-malaria-operational-plan.pdf?sfvrsn=5>).
14. Committee on Gene Drive Research in Non-Human Organisms: Recommendations for Responsible Conduct; Board on Life Sciences; Division on Earth and Life Studies; National Academies of Sciences Engineering and Medicine, “Gene Drives on the Horizon: Advancing Science, Navigating Uncertainty, and Aligning Research with Public Values” (National Academies Press, 2016), doi:10.17226/23405.
15. A. R. North, A. Burt, H. C. J. Godfray, Modelling the potential of genetic control of malaria mosquitoes at national scale. *BioMed Central Biology*. **17**, 1–12 (2019).
16. A. Burt, A. Deredec, Self-limiting population genetic control with sex-linked genome editors. *Proceedings of the Royal Society B: Biological Sciences*. **285** (2018), doi:10.1098/rspb.2018.0776.
17. A. M. Hammond, R. Galizi, Gene drives to fight malaria: current state and future directions. *Pathogens and Global Health*. **111**, 412–423 (2017).
18. C. J. A. Bradshaw, C. R. McMahon, in *Encyclopedia of Ecology, Five-Volume Set* (Elsevier Inc., 2008), pp. 1535–1543.
19. D. Moro, M. Byrne, M. Kennedy, S. Campbell, M. Tizard, Identifying knowledge gaps for gene drive research to control invasive animal species: The next CRISPR step. *Global Ecology and Conservation*. **13** (2018), p. e00363.
20. A. P. Mnzava, T. B. Knox, E. A. Temu, A. Trett, C. Fornadel, J. Hemingway, M. Renshaw, Implementation of the global plan for insecticide resistance management in malaria vectors: progress, challenges and the way forward. *Malaria Journal*. **14**, 173 (2015).
21. A. S. Bhagavathula, A. A. Elnour, A. Shehab, Alternatives to currently used antimalarial drugs: In search of a magic bullet. *Infectious Diseases of Poverty*. **5** (2016), doi:10.1186/s40249-016-0196-8.
22. WHO, Status report on artemisinin resistance (January 2014). *WHO* (2014).
23. N. Protopopoff, J. F. Moshia, E. Lukole, J. D. Charlwood, A. Wright, C. D. Mwalimu, A. Manjurano, F. W.

- Mosha, W. Kisinza, I. Kleinschmidt, M. Rowland, Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. *The Lancet*. **391**, 1577–1588 (2018).
24. ENSSER, “GENE DRIVES A report on their science, applications, social aspects, ethics and regulations” (Bern, 2019), (available at <https://genedrives.ch/wp-content/uploads/2019/10/Gene-Drives-Book-WEB.pdf>).
  25. P. Paes de Andrade, F. José Lima Aragão, W. Colli, O. Antônio Dellagostin, F. Finardi-Filho, M. Hiroyuki Hirata, A. de Castro Lira-Neto, M. Almeida de Melo, A. Lima Nepomuceno, F. Gorgônio da Nóbrega, G. Delfino de Sousa, F. Hercos Valicente, M. Helena Bodanese Zanettini, Use of transgenic *Aedes aegypti* in Brazil: risk perception and assessment. *Bull World Health Organ* (2016), doi:10.2471/BLT.16.173377.
  26. WHO, Progress and prospects for the use of genetically modified mosquitoes to inhibit disease transmission (2009), doi:10.2471/TDR.10.978-924-1599238.
  27. WHO/TDR and FNIH, Guidance framework for testing genetically modified mosquitoes, 159 (2014).
  28. S. James, F. H. Collins, P. A. Welkhoff, C. Emerson, H. C. J Godfray, M. Gottlieb, B. Greenwood, S. W. Lindsay, C. M. Mbogo, F. O. Okumu, H. Quemada, M. Savadogo, J. A. Singh, K. H. Tountas, Y. T. Toure, Pathway to deployment of gene drive mosquitoes as a potential biocontrol tool for elimination of malaria in sub-Saharan Africa: Recommendations of a scientific working group. *American Journal of Tropical Medicine and Hygiene*. **98**, 1–49 (2018).
  29. R. G. A. Feachem, I. Chen, O. Akbari, A. Bertozzi-Villa, S. Bhatt, F. Binka, M. F. Boni, C. Buckee, J. Dieleman, A. Dondorp, A. Eapen, N. Sekhri Feachem, S. Filler, P. Gething, R. Gosling, A. Haakenstad, K. Harvard, A. Hatefi, D. Jamison, K. E. Jones, C. Karema, R. N. Kamwi, A. Lal, E. Larson, M. Lees, N. F. Lobo, A. E. Micah, B. Moonen, G. Newby, X. Ning, M. Pate, M. Quiñones, M. Roh, B. Rolfe, D. Shanks, B. Singh, K. Staley, J. Tulloch, J. Wegbreit, H. J. Woo, W. Mpanju-Shumbusho, Malaria eradication within a generation: ambitious, achievable, and necessary. *The Lancet*. **394**, 1056–1112 (2019).
  30. WHO, *Malaria eradication: benefits , future scenarios A report of the Strategic Advisory Group* (Geneva, 2020).
  31. WHO, *WHO guide to cost-effectiveness analysis* (WHO, Switzerland, 2003);

[https://www.who.int/choice/publications/p\\_2003\\_generalised\\_cea.pdf](https://www.who.int/choice/publications/p_2003_generalised_cea.pdf)).

32. A. Haakenstad, A. C. Harle, G. Tsakalos, A. E. Micah, T. Tao, M. Anjomshoa, J. Cohen, N. Fullman, S. I. Hay, T. Mestrovic, S. Mohammed, S. M. Mousavi, M. R. Nixon, D. Pigott, K. Tran, C. J. L. Murray, J. L. Dieleman, Tracking spending on malaria by source in 106 countries, 2000–16: an economic modelling study. *The Lancet Infectious Diseases*. **19**, 703–716 (2019).
33. C. F. Curtis, Possible Use of Translocations to fix Desirable Genes in Insect Pest Populations. *Nature*, 368–369 (1968).
34. O. S. Akbari, C. H. Chen, J. M. Marshall, H. Huang, I. Antoshechkin, B. A. Hay, Novel synthetic medea selfish genetic elements drive population replacement in drosophila; A theoretical exploration of medea - dependent population suppression. *ACS Synthetic Biology*. **3**, 915–928 (2014).
35. R. Galizi, A. Hammond, K. Kyrou, C. Taxiarchi, F. Bernardini, S. M. O’Loughlin, P. A. Papathanos, T. Nolan, N. Windbichler, A. Crisanti, A CRISPR-Cas9 sex-ratio distortion system for genetic control. *Scientific Reports*. **6** (2016), doi:10.1038/srep31139.
36. A. Pike, Y. Dong, N. B. Dizaji, A. Gacita, E. F. Mongodin, G. Dimopoulos, Changes in the microbiota cause genetically modified Anopheles to spread in a population. *Science*. **357**, 1396–1399 (2017).
37. H. C. J. Godfray, A. North, A. Burt, How driving endonuclease genes can be used to combat pests and disease vectors. *BioMed Central Biology*. **15** (2017), p. 81.
38. M. G. Heffel, G. C. Finnigan, Mathematical modeling of self-contained CRISPR gene drive reversal systems. *Scientific Reports*. **9**, 1–10 (2019).
39. C. Noble, J. Min, J. Olejarz, J. Buchthal, A. Chavez, A. L. Smidler, E. A. DeBenedictis, G. M. Church, M. A. Nowak, K. M. Esvelt, Daisy-chain gene drives for the alteration of local populations. *Proceedings of the National Academy of Sciences of the United States of America*. **116**, 8275–8282 (2019).
40. A. R. North, A. Burt, H. C. J. Godfray, Modelling the potential of genetic control of malaria mosquitoes at national scale. *BioMed Central Biology*. **17**, 26 (2019).
41. P. A. Eckhoff, E. A. Wenger, H. C. J. Godfray, A. Burt, Impact of mosquito gene drive on malaria elimination in a computational model with explicit spatial and temporal dynamics. *Proceedings of the National Academy of Sciences*. **114**, 201611064 (2016).



42. P. B. Thompson, The roles of ethics in gene drive research and governance. *Journal of Responsible Innovation*. **5**, S159–S179 (2018).
43. N. Wedell, T. A. R. Price, A. K. Lindholm, Gene drive: Progress and prospects. *Proceedings of the Royal Society B: Biological Sciences*. **286** (2019), doi:10.1098/rspb.2019.2709.
44. A. Burt, A. Crisanti, Gene Drive: Evolved and Synthetic. *ACS Chemical Biology*. **13**, 343–346 (2018).
45. R. Galizi, L. A. Doyle, M. Menichelli, F. Bernardini, A. Deredec, A. Burt, B. L. Stoddard, N. Windbichler, A. Crisanti, A synthetic sex ratio distortion system for the control of the human malaria mosquito. *Nature Communications*. **5**, 1–8 (2014).
46. A. Simoni, A. M. Hammond, A. K. Beaghton, R. Galizi, C. Taxiarchi, K. Kyrou, D. Meacci, M. Gribble, G. Morselli, A. Burt, T. Nolan, A. Crisanti, A male-biased sex-distorter gene drive for the human malaria vector *Anopheles gambiae*. *Nature Biotechnology*, 1–7 (2020).
47. S. M. Aljunid, S. Srithamrongsawat, W. Chen, S. J. Bae, R. F. Pwu, S. Ikeda, L. Xu, in *Value in Health* (Elsevier, 2012), vol. 15, pp. S132–S138.
48. L. Alphey, M. Benedict, R. Bellini, G. G. Clark, D. A. Dame, M. W. Service, S. L. Dobson, Sterile-insect methods for control of mosquito-borne diseases: An analysis. *Vector-Borne and Zoonotic Diseases*. **10** (2010), pp. 295–311.
49. WHO, *Indoor residual spraying: an operational manual for indoor residual spraying (IRS) for malaria transmission control and elimination – 2nd ed.* (2015); [https://apps.who.int/iris/bitstream/handle/10665/177242/9789241508940\\_eng.pdf;jsessionid=F52653E3A627EEA36605CF75D5DE5FF7?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/177242/9789241508940_eng.pdf;jsessionid=F52653E3A627EEA36605CF75D5DE5FF7?sequence=1)).
50. B. Zelman, A. Kiszewski, C. Cotter, J. Liu, Costs of eliminating malaria and the impact of the global fund in 34 countries. *PloS ONE*. **9**, 1–17 (2014).
51. R. Shretta, B. Zelman, M. L. Birger, A. Haakenstad, L. Singh, Y. Liu, J. Dieleman, Tracking development assistance and government health expenditures for 35 malaria-eliminating countries: 1990-2017. *Malaria Journal*. **16**, 251 (2017).
52. WHO, “Malaria control in complex emergencies: an inter-agency handbook” (2005).

53. M. Carrel, J. Patel, S. M. Taylor, M. Janko, M. K. Mwandagalirwa, A. K. Tshefu, A. A. Escalante, A. McCollum, M. T. Alam, V. Udhayakumar, S. Meshnick, M. Emch, The geography of malaria genetics in the Democratic Republic of Congo: A complex and fragmented landscape. *Social Science and Medicine*. **133**, 233–241 (2015).
54. H. J. W. Sturrock, K. W. Roberts, J. Wegbreit, C. Ohrt, R. D. Gosling, Tackling imported malaria: An elimination endgame. *American Journal of Tropical Medicine and Hygiene*. **93** (2015), pp. 139–144.
55. N. Alphey, L. Alphey, M. B. Bonsall, A Model Framework to Estimate Impact and Cost of Genetics- Based Sterile Insect Methods for Dengue Vector Control Short title : Genetic Vector Control against Dengue, 1–16 (2018).
56. Z. Meghani, C. Boëte, Genetically engineered mosquitoes, Zika and other arboviruses, community engagement, costs, and patents: Ethical issues. *PLoS Neglected Tropical Diseases*. **12**, 1–7 (2018).
57. N. Alphey, L. Alphey, M. B. Bonsall, A model framework to estimate impact and cost of genetics-based sterile insect methods for dengue vector control. *PLoS ONE*. **6** (2011), doi:10.1371/journal.pone.0025384.
58. A. Miles, N. J. Harding, G. Bottà, C. S. Clarkson, T. Antão, K. Kozak, D. R. Schrider, A. D. Kern, S. Redmond, I. Sharakhov, R. D. Pearson, C. Bergey, M. C. Fontaine, M. J. Donnelly, M. K. N. Lawniczak, D. Ayala, N. J. Besansky, A. Burt, B. Caputo, A. Della Torre, H. C. J. Godfray, M. W. Hahn, J. Midega, D. E. Neafsey, S. O’Loughlin, J. Pinto, M. M. Riehle, K. D. Vernick, D. Weetman, C. S. Wilding, B. J. White, A. D. Troco, A. Diabaté, C. Costantini, K. R. Rohatgi, N. Elissa, B. Coulibaly, J. Dinis, C. Mbogo, P. Bejon, H. D. Mawejje, J. Stalker, K. Rockett, E. Drury, D. Mead, A. Jeffreys, C. Hubbart, K. Rowlands, A. T. Isaacs, D. Jyothi, C. Malangone, P. Vauterin, B. Jeffery, I. Wright, L. Hart, K. Kluczyński, V. Cornelius, B. Macinnis, C. Henrichs, R. Giacomantonio, D. P. Kwiatkowski, Genetic diversity of the African malaria vector *Anopheles gambiae*. *Nature*. **552**, 96–100 (2017).
59. C. A. Guerra, R. C. Reiner, T. A. Perkins, S. W. Lindsay, J. T. Midega, O. J. Brady, C. M. Barker, W. K. Reisen, L. C. Harrington, W. Takken, U. Kitron, A. L. Lloyd, S. I. Hay, T. W. Scott, D. L. Smith, A global assembly of adult female mosquito mark-release-recapture data to inform the control of mosquito-borne pathogens. *Parasites and Vectors*. **7**, 1–15 (2014).
60. Institute for Disease Modeling, Epidemiological Modeling Software (2019), (available at <http://idmod.org/software>).

61. P. A. Eckhoff, A malaria transmission-directed model of mosquito life cycle and ecology. *Malaria journal*. **10**, 303 (2011).
62. P. A. Eckhoff, Malaria parasite diversity and transmission intensity affect development of parasitological immunity in a mathematical model. *Malaria Journal*, 1–14 (2012).
63. P. A. Eckhoff, Mathematical models of within-host and transmission dynamics to determine effects of malaria interventions in a variety of transmission settings. *The American Journal of Tropical Medicine and Hygiene*. **88**, 817–827 (2013).
64. USAID, “Democratic Republic Of The Congo Demographic and Health Survey (DRC-DHS II 2013-2014) Supplemental Malaria Report” (2015), (available at [www.DHSprogram.com](http://www.DHSprogram.com)).
65. USAID, “Demographic and Health Survey 2013-14 Key Findings Democratic Republic of Congo” (2015), (available at <http://www.dhsprogram.com>).
66. The Malaria Atlas Project, PR Survey Data - MAP (2018), (available at <https://malariaatlas.org/pr-survey-data/>).
67. QGIS Development Team, QGIS Geographic Information System. *Open Source Geospatial Foundation Project* (2019), (available at <http://qgis.osgeo.org>).
68. School of Geography and Environmental Science, University of Southampton, Democratic Republic of the Congo 100m Population. Alpha version 2010 and 2015 estimates of numbers of people per grid square, with national totals adjusted to match UN population division estimates (<http://esa.un.org/wpp/>) and remaining unadjusted. *WorldPop* (2013), , doi:10.5258/SOTON/WP00072.
69. C. J. M. Koenraadt, A. K. Githeko, W. Takken, The effects of rainfall and evapotranspiration on the temporal dynamics of *Anopheles gambiae* s.s. and *Anopheles arabiensis* in a Kenyan village. *Acta tropica*. **90**, 141–153 (2004).
70. IRI/LDEO, dataset: USGS VCAP eight-day (2019), (available at <https://iridl.ldeo.columbia.edu/SOURCES/.USGS/.VCAP/.eight-day/>).
71. G. Chabot-Couture, K. Nigmatulina, P. Eckhoff, An environmental data set for vector-borne disease modeling and epidemiology. *PLoS ONE*. **9** (2014), doi:10.1371/journal.pone.0094741.

72. S. Bhatt, D. J. Weiss, E. Cameron, D. Bisanzio, B. Mappin, U. Dalrymple, K. E. Battle, C. L. Moyes, A. Henry, P. A. Eckhoff, E. A. Wenger, O. Briët, M. A. Penny, T. A. Smith, A. Bennett, J. Yukich, T. P. Eisele, J. T. Griffin, C. A. Fergus, M. Lynch, F. Lindgren, J. M. Cohen, C. L. J. J. Murray, D. L. Smith, S. I. Hay, R. E. Cibulskis, P. W. Gething, O. Briet, M. A. Penny, T. A. Smith, A. Bennett, J. Yukich, T. P. Eisele, J. T. Griffin, C. A. Fergus, M. Lynch, F. Lindgren, J. M. Cohen, C. L. J. J. Murray, D. L. Smith, S. I. Hay, R. E. Cibulskis, P. W. Gething, The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature*. **526**, 207–211 (2015).
73. WHO, “World Malaria Report” (2010), (available at [https://www.who.int/malaria/world\\_malaria\\_report\\_2010/worldmalariareport2010.pdf?ua=1](https://www.who.int/malaria/world_malaria_report_2010/worldmalariareport2010.pdf?ua=1)).
74. J. Gerardin, P. A. Eckhoff, E. A. Wenger, Mass campaigns with antimalarial drugs: A modelling comparison of artemether-lumefantrine and DHA-piperazine with and without primaquine as tools for malaria control and elimination. *BioMed Central Infectious Diseases*. **15**, 1–14 (2015).
75. D. B. Evans, T. T.-T. Edejer, T. Adam, S. S. Lim, Methods to assess the costs and health effects of interventions for improving health in developing countries. *The British Journal of Medicine*. **331**, 1137–1140 (2005).
76. WHO, Democratic Republic of the Congo Statistics (2016), (available at <http://www.who.int/countries/cod/en/>).
77. GBD 2017 Causes of Death Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*. **390**, 1211–1259 (2017).
78. J. A. Salomon, in *Encyclopedia of Health Economics* (Elsevier, 2014), pp. 200–203.
79. WHO, “WHO methods and data sources for global burden of disease estimates 2000–2015” (2017), (available at [http://www.who.int/gho/mortality\\_burden\\_disease/en/index.html](http://www.who.int/gho/mortality_burden_disease/en/index.html)).
80. C. M. Morel, J. A. Lauer, D. B. Evans, Cost effectiveness analysis of strategies to combat malaria in developing countries. *The British Medical Journal*. **331**, 1–7 (2005).
81. WHO, AFR E: Cost effectiveness results for Malaria. *WHO* (2020), (available at [https://www.who.int/choice/results/mal\\_afre/en/](https://www.who.int/choice/results/mal_afre/en/)).

82. S. L. O'Neill, P. A. Ryan, A. P. Turley, G. Wilson, K. Retzki, I. Iturbe-Ormaetxe, Y. Dong, N. Kenny, C. J. Paton, S. A. Ritchie, J. Brown-Kenyon, D. Stanford, N. Wittmeier, N. P. Jewell, S. K. Tanamas, K. L. Anders, C. P. Simmons, Scaled deployment of *Wolbachia* to protect the community from dengue and other *Aedes* transmitted arboviruses. *Gates Open Research*. **2**, 36 (2018).
83. U.S. Bureau of Labour Statistics, "Consumer Price Index" (2019), (available at [https://www.bls.gov/news.release/archives/cpi\\_12112019.htm](https://www.bls.gov/news.release/archives/cpi_12112019.htm)).

## Acknowledgments

**General:** The authors thank the Institute for Disease Modeling, and in particular Benoit Raybaud and Edward Wenger, for their generous technical support and resource sharing. We are immensely grateful to Philip Welkhoff for helpful discussions and comments on an earlier version of the manuscript.

**Funding:** Federal Ministry for Economic Cooperation and Development via German Academic Exchange Service (DAAD) and the Wellcome Trust.

**Author contributions:** The authors contributed equally to this work.

**Competing interests:** The authors state that there are no competing interests.

## Data and materials availability:

Codes on GitHub:

gene drive: <https://github.com/NaniMet/gene-drive>

dtk-tools: <https://github.com/InstituteForDiseaseModeling/dtk-tools>

EMOD: <https://github.com/InstituteForDiseaseModeling/EMOD>